Mechanisms of Dihydromyricetin Against Hepatocellular Carcinoma Elucidated by Network Pharmacology Combined with Experimental Validation

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2023 Jul 18

PMID 37462387

Authors

Shuo Zhang

Ya-Ning Shi

Jia Gu

Peng He

Qi-di Ai

Xu-Dong Zhou

Wei Wang

Li Qin

Affiliations

Soon will be listed here.

Abstract

Context: Dihydromyricetin (DMY) is extracted from vine tea, a traditional Chinese herbal medicine with anti-cancer, liver protection, and cholesterol-lowering effects.

Objective: This study investigated the mechanism of DMY against hepatocellular carcinoma (HCC).

Materials And Methods: Potential DMY, HCC, and cholesterol targets were collected from relevant databases. PPI networks were created by STRING. Then, the hub genes of co-targets, screened using CytoHubba. GO and KEGG pathway enrichment, were performed by Metascape. Based on the above results, a series of experiments were conducted by using 40-160 μM DMY for 24 h, including transwell migration/invasion assay, western blotting, and Bodipy stain assay.

Results: Network pharmacology identified 98 common targets and 10 hub genes of DMY, HCC, and cholesterol, and revealed that the anti-HCC effect of DMY may be related to the positive regulation of lipid rafts. Further experiments confirmed that DMY inhibits the proliferation, migration, and invasion of HCC cells and reduces their cholesterol levels . The IC is 894.4, 814.4, 467.8, 1,878.8, 151.8, and 156.9 μM for 97H, Hep3B, Sk-Hep1, SMMC-7721, HepG2, and Huh7 cells, respectively. In addition, DMY downregulates the expression of lipid raft markers (CAV1, FLOT1), as well as EGFR, PI3K, Akt, STAT3, and Erk.

Discussion And Conclusion: The present study reveals that DMY suppresses EGFR and its downstream pathways by reducing cholesterol to disrupt lipid rafts, thereby inhibiting HCC, which provides a promising candidate drug with low toxicity for the treatment of HCC.

Citing Articles

Neuroprotective effects of total phenolics from Baroni leaves through the PI3K/AKT pathway.

Jia Y, Wang Y, Wang Z, Zhang Z, Zhang J, Zhang J Front Pharmacol. 2024; 15:1370619.

PMID: 39070797 PMC: 11272554. DOI: 10.3389/fphar.2024.1370619.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Zhang C, Zhu N, Long J, Wu H, Wang Y, Liu B . Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma. Acta Pharmacol Sin. 2020; 42(9):1472-1485. PMC: 8379158. DOI: 10.1038/s41401-020-00572-6. View

Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S . Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 1990; 50(11):3270-3. View

Nielsen S, Nordestgaard B, Bojesen S . Statin use and reduced cancer-related mortality. N Engl J Med. 2012; 367(19):1792-802. DOI: 10.1056/NEJMoa1201735. View

Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok M . Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 2022; 19(7):834-847. PMC: 9243114. DOI: 10.1038/s41423-022-00872-3. View

Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C . The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 2019; 60:41-56. DOI: 10.1016/j.semcancer.2019.10.002. View

Zhang X, Wang L, Peng L, Tian X, Qiu X, Cao H . Dihydromyricetin protects HUVECs of oxidative damage induced by sodium nitroprusside through activating PI3K/Akt/FoxO3a signalling pathway. J Cell Mol Med. 2019; 23(7):4829-4838. PMC: 6584490. DOI: 10.1111/jcmm.14406. View

Liu J, Shu Y, Zhang Q, Liu B, Xia J, Qiu M . Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncol Lett. 2014; 8(4):1645-1651. PMC: 4156277. DOI: 10.3892/ol.2014.2330. View

Shoukat S, Zheng D, Yusuf S . Cardiotoxicity Related to Radiation Therapy. Cardiol Clin. 2019; 37(4):449-458. DOI: 10.1016/j.ccl.2019.07.010. View

10.

Hryniewicz-Jankowska A, Augoff K, Sikorski A . The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer. Exp Biol Med (Maywood). 2019; 244(13):1053-1061. PMC: 6775568. DOI: 10.1177/1535370219870771. View

11.

Huang C, Su C, Wang P, Lu Y, Ho Y, Yang S . Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases-2 expression in human nasopharyngeal carcinoma through extracellular signal-regulated kinase signaling pathway. Environ Toxicol. 2022; 37(5):1244-1253. DOI: 10.1002/tox.23480. View

12.

Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F . The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020; 5(1):87. PMC: 7292831. DOI: 10.1038/s41392-020-0187-x. View

13.

Bentzen S . Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006; 6(9):702-13. DOI: 10.1038/nrc1950. View

14.

Xu L, Zhang Y, Liu J, Qu J, Hu X, Zhang F . TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur J Cancer. 2012; 48(17):3288-99. DOI: 10.1016/j.ejca.2012.03.005. View

15.

Jiang L, Zhang Q, Ren H, Ma S, Lu C, Liu B . Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. PLoS One. 2015; 10(4):e0124994. PMC: 4411137. DOI: 10.1371/journal.pone.0124994. View

16.

Luo J, Yang H, Song B . Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2019; 21(4):225-245. DOI: 10.1038/s41580-019-0190-7. View

17.

Ye L, Yin G, Jiang M, Tu B, Li Z, Wang Y . Dihydromyricetin Exhibits Antitumor Activity in Nasopharyngeal Cancer Cell Through Antagonizing Wnt/β-catenin Signaling. Integr Cancer Ther. 2021; 20:1534735421991217. PMC: 7975991. DOI: 10.1177/1534735421991217. View

18.

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

19.

Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson N . Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci. 2017; 18(2). PMC: 5343994. DOI: 10.3390/ijms18020461. View

20.

Mok E, Leung C, Zhou L, Lei M, Leung H, Tong M . Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma. Cancer Res. 2022; 82(17):3102-3115. DOI: 10.1158/0008-5472.CAN-21-2934. View